Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects

200621 citationsJournal Article

Authors

There were no relevant pharmacokinetic interactions between roflumilast and salbutamol at therapeutically effective doses.

Good health and well-being

Published in: International Journal of Clinical Pharmacology and Therapeutics

Volume 44, Issue 11, pp. 572-579

Field-Weighted Citation Impact: 1.00